

# Talia Golan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/449681/talia-golan-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121  
papers

4,938  
citations

26  
h-index

69  
g-index

140  
ext. papers

6,979  
ext. citations

5.5  
avg, IF

5.26  
L-index

#	Paper	IF	Citations
121	Benefit for single-agent adjuvant chemotherapy in elderly patients with locally advanced gastric adenocarcinoma.. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2022</b> , 1	4.9	
120	Open-label phase 1/2 study evaluating the tolerability and antitumor activity of selinexor and pembrolizumab in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 110-110	2.2	
119	Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.. <i>Nature Cancer</i> , <b>2022</b> ,	15.4	2
118	Coeliac plexus radiosurgery for pain management in patients with advanced cancer : study protocol for a phase II clinical trial.. <i>BMJ Open</i> , <b>2022</b> , 12, e050169	3	
117	Patient-derived xenograft models of BRCA-associated pancreatic cancers. <i>Advanced Drug Delivery Reviews</i> , <b>2021</b> , 171, 257-265	18.5	2
116	Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e15579-e15579	2.2	0
115	A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3584-3584	2.2	7
114	Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. <i>JAMA Oncology</i> , <b>2021</b> , 7, 693-699	13.4	19
113	Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. <i>Gastroenterology</i> , <b>2021</b> , 160, 2119-2132.e9	13.3	30
112	Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1904-1911	12.9	6
111	Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma. <i>Oncologist</i> , <b>2021</b> , 26, e111-e114	5.7	
110	Mortality Among Neutropenic Cancer Patients Within the United States: The Association With Hospital Volume. <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e582-e592	2.3	0
109	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 412-412	2.2	1
108	Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 378-378	2.2	29
107	Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 420-420	2.2	1
106	AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with Inhibition. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 565-572	6.6	2
105	Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2617-2631	2.2	15

104	The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 2166-2176	6.1	2
103	Management of BRCA Mutation Carriers With Pancreatic Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 469-473	7.3	0
102	Targeting homologous recombination addicted tumors: challenges and opportunities.. <i>Annals of Pancreatic Cancer</i> , <b>2020</b> , 3,	1.3	2
101	The human tumor microbiome is composed of tumor type-specific intracellular bacteria. <i>Science</i> , <b>2020</b> , 368, 973-980	33.3	379
100	Moving Beyond Chemotherapy for Pancreaticobiliary Tumors: Targeted and Immunotherapy Strategies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , e333-e343	7.1	1
99	Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 599-604	2.6	4
98	Geographic and Ethnic Heterogeneity of Germline or Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1442-1454	2.2	22
97	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1378-1388	2.2	136
96	Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 1411-1420	4.3	9
95	ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 3971-3972	3.1	1
94	Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 3963-3970	3.1	22
93	A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS4672-TPS4672	2.2	15
92	A randomized, multicenter, phase II trial of gemcitabine (G), cisplatin (C) +/- veliparib (V) in patients with pancreas adenocarcinoma (PDAC) and a known germline (g)BRCA/ PALB2 mutation.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 639-639	2.2	7
91	Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 648-648	2.2	1
90	Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 686-686	2.2	
89	The impact of pancreatic cancer resection in the era of effective systemic treatment.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 722-722	2.2	
88	Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 750-750	2.2	1
87	Effect of the botanical compound LCS102 on innate immunity. <i>Biomedical Reports</i> , <b>2020</b> , 13, 17	1.8	

86	POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4626-4626	2.2	1
85	A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS3160-TPS3160	2.2	1
84	A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS3147-TPS3147	2.2	1
83	Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4621-4621	2.2	
82	POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e16800-e16800	2.2	
81	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , <b>2020</b> , 26, 878-885	50.5	126
80	Clinical Characteristics and Prognosis of Gastric Cancer Patients with Germline Mutations: Report of Ten Cases and a Literature Review. <i>OncoTargets and Therapy</i> , <b>2020</b> , 13, 11637-11644	4.4	4
79	A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5462-5476	12.9	14
78	Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). <i>European Journal of Cancer</i> , <b>2020</b> , 137, 272-284	7.5	32
77	Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. <i>European Journal of Cancer</i> , <b>2019</b> , 120, 122-131	7.5	36
76	Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. <i>Cancer Cell</i> , <b>2019</b> , 35, 267-282.e7	24.3	80
75	Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent?. <i>Molecular and Clinical Oncology</i> , <b>2019</b> , 10, 555-559	1.6	1
74	Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e300-e307	3.8	4
73	Maintenance Olaparib for Germline -Mutated Metastatic Pancreatic Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 317-327	59.2	826
72	Postoperative Radiation for Pathologic Stage T4 Colon Cancers Receiving Adjuvant Chemotherapy. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 226-230.e2	3.8	2
71	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , <b>2019</b> , 156, 2242-2253.e4	13.3	117
70	Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. <i>Gastric Cancer</i> , <b>2019</b> , 22, 828-837	7.6	112
69	Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 2029-2041	6.6	21

68	Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. <i>Cancer Research</i> , <b>2019</b> , 79, 4491-4502	10.1	18
67	Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2528-2528	2.2	12
66	Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4009-4009	2.2	10
65	Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 9509-9509	2.2	18
64	Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, LBA4-LBA4	2.2	8
63	The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts. <i>Oncotarget</i> , <b>2019</b> , 10, 6269-6282	3.3	1
62	Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliative and functional outcomesFinal results of a prospective clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 309-309	2.2	0
61	Celiac plexus radiosurgery for pain management in advanced cancer patients: An international phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS466-TPS466	2.2	
60	Lung metastasis as predictor for prognosis in metastatic colorectal cancer with mutated KRAS.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 636-636	2.2	
59	Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. <i>Oncologist</i> , <b>2019</b> , 24, e671-e676	5.7	1
58	Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 94, 1-5	7.5	21
57	Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 179-183	7.5	11
56	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. <i>Cancer</i> , <b>2018</b> , 124, 1374-1382	6.4	67
55	Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 16	17.4	53
54	A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer. <i>European Journal of Cancer</i> , <b>2018</b> , 96, 105-110	7.5	4
53	Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. <i>Cancer</i> , <b>2018</b> , 124, 491-498	6.4	4
52	LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2018</b> , 9, 871-879	10.3	46
51	Celiac plexus radiosurgery: A new palliative modality for upper gastrointestinal malignanciesFinal results of a proof-of-concept clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 10098-10098	2.2	1

50	Geographic and ethnic heterogeneity in the BRCA1/2 pre-screening population for the randomized phase III POLO study of olaparib maintenance in metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4115-4115	2.2	9
49	Phase II study of olaparib for BRCAness phenotype in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 297-297	2.2	23
48	Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 92-92	2.2	15
47	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 88-88	2.2	4
46	Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 271-271	2.2	
45	A new look at the IDEA classification: Defining novel predictive and prognostic markers in stage III colon cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 845-845	2.2	
44	Evaluation of pharmacodynamic (PD) biomarkers in patients with metastatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 276-276	2.2	1
43	KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors Asian subgroup analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 723-723	2.2	1
42	Refining the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15686-e15686	2.2	
41	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , <b>2018</b> , 89, 19-26	7.5	98
40	Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 697-702	8.7	49
39	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. <i>Oncologist</i> , <b>2017</b> , 22, 804-810	5.7	65
38	DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 1063-1069	7.3	19
37	Exclusive destruction of mitotic spindles in human cancer cells. <i>Oncotarget</i> , <b>2017</b> , 8, 20813-20824	3.3	12
36	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , <b>2017</b> , 357, 1156-1160	33.3	577
35	Short- and Long-Term Survival in Metastatic Pancreatic Adenocarcinoma, 1993-2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2017</b> , 15, 1022-1027	7.3	20
34	KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4003-4003	2.2	102
33	KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4012-4012	2.2	39

32	Short and long-term survival in metastatic pancreatic adenocarcinoma, 1993-2013.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 232-232	2.2	3
31	Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease. <i>Oncotarget</i> , <b>2017</b> , 8, 40778-40790	3.3	18
30	ATM as a biomarker for DNA damage repair deficiency in pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 308-308	2.2	
29	Changing the course of pancreatic cancer--Focus on recent translational advances. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 44, 17-25	14.4	19
28	Identification of tissue-specific cell death using methylation patterns of circulating DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E1826-34	11.5	35 <sup>0</sup>
27	Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 133-8	4.4	14
26	POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4152-TPS4152	2.2	11
25	Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 244-244	2.2	
24	Effect of hospital volume on mortality rates amongst neutropenic cancer patients within the United States.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 6600-6600	2.2	
23	Clinical experience with pembrolizumab in metastatic heavily pre-treated patients with solid cancers in a single center.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14549-e14549	2.2	
22	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 717-726	21.7	716
21	Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 157, 157-65	4.4	36
20	Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients. <i>Cancer Medicine</i> , <b>2015</b> , 4, 1472-83	4.8	37
19	Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study. <i>BioMed Research International</i> , <b>2015</b> , 2015, 681653	3	5
18	RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. <i>Oncotarget</i> , <b>2015</b> , 6, 24560-70	3.3	17 <sup>0</sup>
17	POLO: A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2 mutation (gBRCAm) who have not progressed following first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS4149-TPS4149	2.2	7
16	Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 358-358	2.2	1
15	Overall survival and clinical characteristics in BRCA mutation carriers with stage I/II pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 287-287	2.2	

14	Diffusion tensor magnetic resonance imaging of the pancreas. <i>PLoS ONE</i> , <b>2014</b> , 9, e115783	3.7	20
13	Does pathologic complete response predict for outcome in BRCA mutation carriers with triple-negative breast cancer?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1023-1023	2.2	6
12	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4023-4023	2.2	16
11	Novel Kras-directed therapy in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 270-270	2.2	2
10	RNA-seq and KRAS mutational status in ascitic pancreatic cancer cells: Novel results and distinct subsets.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15214-e15214	2.2	1
9	The role of adjuvant radiation therapy in T4 nonrectal colon cancers.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 553-553	2.2	
8	Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location. <i>Cancer</i> , <b>2013</b> , 119, 3084-91	6.4	40
7	A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4037-4037	2.2	10
6	Randomized phase II study of gemcitabine (G), cisplatin (C) with or without veliparib (V) (arms A, B) and a phase II single-arm study of single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4144-TPS4144	2.2	3
5	Chemosensitivity and clinical characteristics of pancreatic malignancies in BRCA mutation carriers.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 278-278	2.2	1
4	Changing prognosis of metastatic colorectal adenocarcinoma (mCRC) 1988-2008 within the general population: Has everyone benefitted?. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14143-e14143	2.2	1
3	Ascitic derived primary pancreatic cancer cell cultures from different patients as a platform for personalized medicine.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14646-e14646	2.2	
2	Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3027-3027	2.2	1
1	Targeting the insulin growth factor pathway in gastrointestinal cancers. <i>Oncology</i> , <b>2011</b> , 25, 518-26, 529	1.8	14